Effect of Intravenous Ferric Carboxymaltose on Hemoglobin Response and Transfusion in Patients With Iron Deficiency Anemia After Off-Pump Coronary Artery Bypass Grafting

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE4

Total Enrollment

100 participants

Study Classification

INTERVENTIONAL

Study Start Date

2019-02-10

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this prospective open-label randomized tral, 100 patients with elective off-pump coronary artery bypass (OPCAB) or minimal invasive direct coronary bypass (MIDCAB) surgery were enrolled. Before surgery, if a patient had iron deficiency anemia, the patient was randomized to receive Ferinject®(Ferric carboxymaltose, n=50) or placebo (normal saline, n=50), respectively. A single dose should not exceed 1000mg of iron per day or 20mg per kg body weight. In addition, the administration of 1000mg of iron should not exceed once a week. Administration to patients with hemodialysis-dependent chronic kidney disease is once daily, and the maximum dose should not exceed 200 mg (4 ml) of iron. Patients weighing less than 35 kg should not exceed 500 mg total iron dose. It uses intravenous infusion and can be administered up to 1,000mg (20ml) as the maximum iron once. For intravenous infusion, this drug is diluted with 0.9% sterile physiological saline solution.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Intravenous Iron for Treatment of Anaemia Before Cardiac Surgery

NCT02632760

Anaemia

COMPLETED PHASE4

Effect of Non-anemic Iron Deficiency on Outcome Following Off-pump Coronary Revascularization

NCT06399627

Coronary Artery Bypass, Off-Pump Iron Deficiencies

RECRUITING

Effects of Oral Iron on Postoperative Fatigue Upon Coronary Artery Bypass Graft Patients

NCT01912261

Fatigue

TERMINATED PHASE3

Preoperative Intravenous Ferric Carboxymaltose and Placebo in the Treatment of Patients Undergoing Cardiac Surgery

NCT03574311

Coronary Artery Disease Postoperative Complications Aortic Valve Stenosis +2 more

UNKNOWN PHASE4

Oral and Intravenous Iron in Patients Postoperative Cardiovascular Surgery Under Extracorporeal Circulation

NCT01078818

Anaemia

COMPLETED PHASE4

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

* Perioperative blood loss and iatrogenic hemodilution lead to postoperative anemia which correlates with infections, and poor physical function, mobility and recovery with subsequent increases in the length of hospital stay and mortality. Preoperative anemia management reduce intraoperative blood loss such as normothermia, antifibrinolytics and cell salvage are key strategies to ameliorate postoperative anemia.
* Patient screening method Off-pump coronary artery bypass (OPCAB) under median-sternotomy, or minimal invasive direct coronary bypass (MIDCAB) undertaken under median-sternotomy Among them, the selection/exclusion criteria are checked and the subjects of the study are screened. \* Inclusion/ exclusion criteria \*\*Inclusion:

* Patients with Preoperative iron deficiency anemia Among Patients scheduled for cardiopulmonary coronary artery bypass graft under median sternotomy in cardiovascular surgery \*\*Exclusion: - a) Patients who underwent iron correction treatment (oral, injection, blood transfusion) within 2 months prior to surgery b) Patients taking anticoagulants before surgery c) Patients taking and administering drugs that can cause bone marrow suppression, such as anticancer drugs, before surgery d) Patients with chronic liver disease and chronic kidney disease undergoing dialysis e) Patients scheduled for coronary artery bypass graft for emergency surgery f) Patients with a history of hypersensitivity reactions and side effects to iron drugs g) Minor (under 20 years old) 3) Definition of iron deficiency anemia (if all criteria a to c in the following items are satisfied)

1. Ferritin\<300mcg/L
2. Transferrin saturation\<25%
3. Hb\<12.0g/dL for women or Hb\<13.0g/dL for men \* The primary goal of this study was the effect of intravenous administration of ferric carboxymaltose on postoperative hemoglobin levels in patients with preoperative iron deficiency anemia among patients requiring cardiopulmonary coronary artery bypass grafting due to coronary artery disease. It is to analyze the effect compared to the control.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coronary Artery Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

In cardiac surgery, patients were randomized to receive Ferinject or placebo (n=50), respectively. The selected agent was intravenous infusion in general ward, preoperatively.

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Patients were offered the allocated treatment for ferric carboxymaltose or not, using the block randomization system. The selected agent was infused to patients after randomization.

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Ferinject®

Group Type EXPERIMENTAL

Ferinject

Intervention Type DRUG

Ferric carboxymaltose injection

Normal saline

Group Type PLACEBO_COMPARATOR

Normal Saline Flush

Intervention Type DRUG

placebo

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ferinject

Ferric carboxymaltose injection

Intervention Type DRUG

Normal Saline Flush

placebo

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Colloidal solution of the iron complex ferric carboxymaltose placebo comparator

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. patients aged 19 years or older
2. undergoing elective OPCAB or MIDCAB surgery with multi-vessel coronary artery disease.

Exclusion Criteria

1. Patients who underwent iron correction treatment (oral, injection, blood transfusion) within 2 months prior to surgery
2. Patients taking anticoagulants before surgery
3. Patients taking and administering drugs that can cause bone marrow suppression, such as anticancer drugs, before surgery
4. Patients with chronic liver disease and chronic kidney disease undergoing dialysis
5. Patients scheduled for coronary artery bypass graft for emergency surgery
6. Patients with a history of hypersensitivity reactions and side effects to iron drugs
7. Minor (under 20 years old)
8. Definition of iron deficiency anemia (if all criteria a to c in the following items are satisfied)

1. Ferritin\<300mcg/L
2. Transferrin saturation\<25%
3. Hb\<12.0g/dL for women or Hb\<13.0g/dL for men

Minimum Eligible Age

19 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No